Acute NAION (Non-Arteritic Ischemic optic Neuropathy) Patients needed for a New Study
The Galassia-NGF-NAION-301 study is a Phase 3, randomized, double-masked trial evaluating intranasal Cenegermin (rhNGF) in adults with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).
Please note that patients must be assessed for the study within 14 days of symptom onset. Participants will use the study medication for 2 months, for a total study duration of 6 months.
Location:
NeuroEyeOrbit Institute
8631 W 3rd Street, Ste 200E, Los Angeles, CA 90048
Inclusion Criteria:
- Men and women aged 50–80 years
- Diagnosis of unilateral NAION with onset within 14 days- BCVA in the study eye > 15 letters and < 65 on ETDRS (to be confirmed at site)
Exclusion Criteria:
- Bilateral or sequential NAION (fellow eye involvement within 6 weeks of study eye)
- IOP > 25 mmHg or history of glaucoma in the study eye
- Giant Cell Arteritis or AMD in the study eye
If you have patients who may be suitable candidates, I would greatly appreciate your referrals. Please feel free to call or text my office staff or me with any questions.
PI: Swaraj Bose, MD
Office: 310 469 9080
EMail: sbose@neuroeyeorbit.com
You Might Also Enjoy...
Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban
COVID-19 and Your Eye Care
COVID-19 Update
What is Thyroid Eye Disease?
